Therapeutic Advances for Pancreatic Cancer: a Slow and Challenging Feat that Continues to Evolve.

Despite precision medicine and advances in oncology such as immunotherapy and targeted therapy that have made substantial strides in certain solid malignancies, effective treatment options are still needed for pancreatic cancer, a highly-lethal disease with a dismal prognosis. Current treatment regimens with antimetabolites and taxanes have only modestly improved survival rates, and surgery remains the only curative measure, with just a minority of patients being eligible for curative surgery at the time of diagnosis. The role of traditional anti-cancer approaches such as radiation has yet to be definitively determined for this malignancy, and more contemporary approaches such as targeted therapy are limited in pancreatic cancer. Exploring alternate expression pathways that can be selectively targeted along with the combination of existing strategies with checkpoint inhibition or CAR-T technology, for example, may prove to be successful in making significant headway for this disease.